Crinetics Pharmaceuticals (CRNX) Capital Expenditures (2017 - 2026)

Crinetics Pharmaceuticals' Capital Expenditures history runs 10 years deep, the most recent figure standing at $464000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures rose 75.76% year-over-year to $464000.0; the TTM figure through Mar 2026 stood at $6.0 million (up 51.32% YoY), while the FY2025 annual figure was $5.8 million, up 49.9% from the prior year.
• Capital Expenditures was $464000.0 for Q1 2026 at Crinetics Pharmaceuticals, down from $5.7 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $5.7 million in Q4 2025 to a low of -$4.4 million in Q3 2025.
• Historically, Capital Expenditures has averaged $741058.8 across 5 years, with a median of $464000.0 in 2026.
• The sharpest annual moves came in 2022 and 2025: Capital Expenditures surged 8766.67% in 2022, then tumbled 930.3% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $1.6 million in 2022, then sank by 280.51% to -$2.9 million in 2023, then surged by 135.72% to $1.0 million in 2024, then soared by 454.42% to $5.7 million in 2025, then tumbled by 91.87% to $464000.0 in 2026.
• The last three Capital Expenditures figures came in at $464000.0 (Q1 2026), $5.7 million (Q4 2025), and -$4.4 million (Q3 2025), per Business Quant data.